Herbal supplements direct-seller Nature's Sunshine Q3 revenue beats estimates, powered by digital sales growth

Reuters
2025/11/07
Herbal supplements direct-seller Nature's Sunshine Q3 revenue beats estimates, powered by digital sales growth

Overview

  • Nature's Sunshine Products Q3 net sales up 12% to $128.3 mln, beating analyst expectations

  • Adjusted EBITDA for Q3 rises 42% to $15.2 mln, exceeding analyst estimates

  • Company raises full-year outlook for 2025 net sales and adjusted EBITDA

Outlook

  • Natures Sunshine raises 2025 net sales forecast to $476-$480 mln from $460-$475 mln

  • Company increases 2025 adjusted EBITDA guidance to $47-$49 mln from $41-$45 mln

Result Drivers

  • DIGITAL SALES - Strategic investments in North America Digital led to a 52% increase in digital sales

  • ASIA-PACIFIC GROWTH - Exceptional results in Asia-Pacific driven by 30%+ growth in Japan and China

  • COST SAVINGS - Cost-saving initiatives increased gross margin by 200 basis points to 73.3%

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$128.30 mln

$120.30 mln (2 Analysts)

Q3 Net Income

$5.30 mln

Q3 Adjusted EBITDA

Beat

$15.20 mln

$10.49 mln (2 Analysts)

Q3 Gross Margin

73.30%

Q3 Operating Income

$9 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the food processing peer group is "buy"

  • Wall Street's median 12-month price target for Nature's Sunshine Products Inc is $21.50, about 34.3% above its November 5 closing price of $14.13

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nGNX5p3vtv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10